|
06 Dec 2020 |
IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting
|
|
06 Dec 2020 |
Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
|
|
06 Dec 2020 |
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
|
|
06 Dec 2020 |
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
|
|
06 Dec 2020 |
Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020
|
|
05 Dec 2020 |
Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX®▼ (daratumumab) Subcutaneous Formulation Regimen After First or Subsequent Relapse in Multiple Myeloma
|
|
04 Dec 2020 |
F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial
|
|
04 Dec 2020 |
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
|
|
04 Dec 2020 |
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
|
|
04 Dec 2020 |
Approved IND for Alligator Bioscience's CD40-targeting antibody mitazalimab
|
|
03 Dec 2020 |
Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
|
|
03 Dec 2020 |
Memo Therapeutics AG’s Antibody Against SARS-CoV-2 Demonstrates Potent Therapeutic and Prophylactic Activity in Advanced COVID-19 Disease Model
|
|
02 Dec 2020 |
Obiltoxaximab Receives Marketing Authorization From European Commission For The Treatment Of Inhalation Anthrax
|
|
02 Dec 2020 |
Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps
|
|
02 Dec 2020 |
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
|
|
01 Dec 2020 |
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
|
|
01 Dec 2020 |
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
|
|
01 Dec 2020 |
Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
|
|
01 Dec 2020 |
Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate
|
|
01 Dec 2020 |
Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
|
|
01 Dec 2020 |
SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
|
|
01 Dec 2020 |
Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer
|
|
27 Nov 2020 |
AbbVie and Eisai Announce an approval for additional indication of HUMIRA®, a fully Human Anti-TNFα Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world
|
|
26 Nov 2020 |
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
|
|
26 Nov 2020 |
Celltrion completes enrolment for global Phase II clinical trial with COVID-19 treatment candidate CT-P59
|
